Chronic Kidney Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older, of any gender.
- People who are willing and able to sign a written consent form to take part in the study.
- People with a confirmed diagnosis of chronic kidney disease (CKD), shown by either reduced kidney function lasting at least 3 months, or signs of kidney damage (such as protein in the urine, abnormal kidney imaging, or kidney biopsy results) lasting at least 3 months (confirm with trial site for exact measurements).
Who may not be able to join:
- People with a serious life-threatening illness where life expectancy is less than 2 years.
- People with severe heart conditions, including dangerous heart rhythm problems, or a major heart or stroke event (such as a heart attack, stroke, or heart-related death) within the past 3 months.
- People who are currently pregnant or breastfeeding.
- People who are currently taking part in another clinical trial, or who have received an experimental treatment within the past 3 months.
- People whose primary condition at the time of joining is end-stage kidney disease, kidney replacement therapy (such as dialysis), sudden (acute) kidney injury, or a kidney condition that has been present for 3 months or less.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiao Qiang Ding, Zhongshan Hospital Affiliated with Fudan University
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively; Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i); Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK; Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK; Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK; Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK; Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK; Clinical outcomes of CKD patients and CKD patients with...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.